RE:RE:RE:RE:RE:RE:RE:Cytodyn down
Wino115 wrote: Everything approved so far is pretty marginal in lowering mortality or hospital duration if you become severe or worse. In fact, NIH 4 days ago stopped plasma trials as they showed zero effect, remdesivir is only for mild, and steroids are very marginal and all they use down here. Still a wide open field for someone to develop good treatment options for severe. Someone will get there hopefully as this virus ain't going away.
FWIW, I like RIGL's chances. Solid rationale established by independent research pointing at major role of the SYK pathway in covid-19-associated ARDS. Fostamatinib already on the market, could see EUA. Rigel runs its own P3, NIH runs a P2 with topline results expected in April.